18:32 , Sep 7, 2018 |  BC Week In Review  |  Company News

Osaka University grants Otsuka rights to MMG49

Osaka University (Osaka, Japan) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) exclusive, worldwide rights to patents associated with MMG49, a CAR T cell therapy that targets the active conformer of integrin β(7). The university will...
17:56 , Sep 7, 2018 |  BC Week In Review  |  Company News

Letter prompts new manufacturing concerns for Fosun

A second manufacturing scandal in as many weeks involving alleged falsification of manufacturing records drove down shares of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) on Aug. 31. According to media reports, self-identified employees...
17:44 , Sep 7, 2018 |  BC Week In Review  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
21:04 , Aug 31, 2018 |  BC Extra  |  Company News

Manufacturing questions for Fosun subsidiary resurface

A second manufacturing scandal in as many weeks involving alleged falsification of manufacturing records drove down shares of Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) on Friday. According to media reports, self-identified employees of...
18:07 , Aug 31, 2018 |  BC Week In Review  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements for...
15:12 , Aug 31, 2018 |  BC Extra  |  Company News

Alkermes in pay-for-performance deal

Alkermes plc (NASDAQ:ALKS) signed a contract with UPMC Health Plan for opioid antagonist Vivitrol naltrexone that links reimbursement of the drug to positive clinical outcomes when treating opioid dependence. Alkermes spokesperson Matthew Henson did not disclose...
21:59 , Aug 24, 2018 |  BC Extra  |  Company News

Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements

The Oklahoma Health Care Authority (OHCA) said it has signed its first contract to negotiate value-based Medicaid purchasing agreements with Alkermes plc (NASDAQ:ALKS) for schizophrenia drug Aristada aripiprazole lauroxil. OHCA is also close to agreements for...
17:04 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
17:41 , Jul 31, 2018 |  BC Extra  |  Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Otsuka acquiring antibody play Visterra

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) is acquiring antibody developer Visterra Inc. (Waltham, Mass.) for $430 million in cash, the companies said on July 11. The deal gives Otsuka a pipeline based on Visterra's Hierotope platform,...